Navigation Links
Codexis, Arch Announce Expanded Collaboration
Date:8/25/2008

REDWOOD CITY, Calif. and MUMBAI, India, Aug. 25 /PRNewswire/ -- Codexis, Inc., a leader in biocatalysis technology, and Arch Pharmalabs Limited, a leading Indian active pharmaceutical ingredients (APIs) and intermediates manufacturer, today announced a major new strategic collaboration, expanding their three-year partnership in pharmaceuticals manufacturing.

Codexis, based in Redwood City, CA, will offer multiple pharmaceutical intermediates and active pharmaceutical ingredients (APIs) made with its proprietary biocatalytic processes to both innovator and generic drug manufacturers. Sales in India will be through its subsidiary, Codexis Laboratories India Private Limited. Arch, which is based in Mumbai, India and has ten facilities throughout the country, will be Codexis' exclusive manufacturer for these products. The two companies will also co-market products.

"Codexis and Arch will now offer a broad range of competitively-priced drug ingredients to the global pharmaceutical industry. We believe this collaboration offers a major opportunity for growth," said Alan Shaw, Ph.D., President and Chief Executive Officer of Codexis. "Market drivers for both the innovator and generics sectors of the global pharmaceutical market are converging, as both sectors accelerate their search for high quality manufacturing at the lowest possible cost. This new agreement is targeted at addressing this convergence, coupling proven biocatalysis technology with large-scale manufacturing capability. We are very pleased to be broadening our collaboration with Arch, which has become an important strategic partner."

"Codexis and Arch have built a successful partnership over three years based on anticipating customer needs and consistently meeting them in the rapidly-growing global market for high quality, low-cost pharmaceutical intermediates and APIs," said Ajit Kamath, Chairman and Managing Director, Arch Pharmalabs Limited. "We are now well-positioned to build
'/>"/>

SOURCE Codexis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
2. Anthill Technologies Announces Agreement With Zafgen
3. Baxter Announces Licensing Agreement for Innocolls Gentamicin Surgical Implant in the United States
4. Cell Therapeutics, Inc. Announces Reverse Stock Split
5. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
6. Regenesis Biomedical Announces Additions to Board of Directors
7. Cryo-Cell International and EndGenitor Technologies Announce Research Collaboration
8. BioMarin Announces Roll-Out of National PKU Registry
9. Bioheart, Inc. Announces Additional Funding Support
10. Biopure Announces 2008 Third Quarter Financial Results
11. Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... DTS Language Services, Inc . is pleased to ... Science organizations who need document translations. Clients will now ... documents in advance with a selection of nearly 50 life ... a critical factor in clinical and scientific fields, and decrease ...
(Date:1/14/2014)... January 14, 2014 Date: Friday, April 11, ... Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... organization solely dedicated to finding a cure for hepatitis B ... will host its annual Crystal Ball on Friday, April 11 ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
(Date:1/14/2014)... WESTBOROUGH, Mass. , Jan. 14, 2014  RXi ... on discovering, developing and commercializing innovative therapies addressing ... announced that it received the Notice of Allowance ... on its unique self-delivering RNAi compounds (sd-rxRNA®), for ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... Newly formed Advisory Board to advise on cancer screening ... mitochondrial DNA-based ... Inc. (OTC,Bulletin Board: TBIO) today announced that it has ... the latest developments and,scientific opportunities in cancer detection screening ...
... ... Use, LA JOLLA, Calif., Jan. 17 Stemagen, a privately ... in the world to create, and meticulously document, a cloned human,embryo ... Wood, M.D., Ph.D., a co-author of the,publication and a donor of ...
... Trial will also Support a Marketing Authorization Application in the ... ... Agennix Incorporated announced today,that the U.S. Food and Drug Administration ... evaluating its lead molecule,talactoferrin alfa, in combination with chemotherapy as first-line,treatment ...
Cached Biology Technology:Transgenomic, Inc. Forms Scientific Advisory Board 2Transgenomic, Inc. Forms Scientific Advisory Board 3Stemagen First to Create Cloned Human Embryos From Adult Cells 2Stemagen First to Create Cloned Human Embryos From Adult Cells 3Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 2Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 3Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 4Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 5
(Date:4/18/2014)... while feeding a world population predicted to reach ... approach to conservation that considers human-altered landscapes such ... and the natural habitat that supports it might ... where at least three-quarters of the land surface ... is vulnerable to human-caused impacts such as climate ...
(Date:4/18/2014)... to the story of how barnyard chickens came to be, ... journal Proceedings of the National Academy of Sciences . ... 200-2300 years ago in Europe, researchers report that just a ... different from the chickens we know today. , The results ... domestic chickens -- such as their yellowish skin -- only ...
(Date:4/18/2014)... Asteroid and comet impacts can cause widespread ecological ... even global scales. But new research from Brown University ... ancient life at the time of an impact. , ... has found fragments of leaves and preserved organic compounds ... in Argentina. The material could provide a snapshot of ...
Breaking Biology News(10 mins):Stanford researchers rethink 'natural' habitat for wildlife 2Stanford researchers rethink 'natural' habitat for wildlife 3Stanford researchers rethink 'natural' habitat for wildlife 4Ancient DNA offers clues to how barnyard chickens came to be 2Impact glass stores biodata for millions of years 2Impact glass stores biodata for millions of years 3
... form of skin cancer, can be successfully treated in some ... work and why they are only effective in some patients ... articles in the January 17 issue of the Journal of ... of immune cells called killer T cells that can attack ...
... with high-risk breast cancer treated with radical mastectomy and ... better survival outcomes with few long-term toxic effects, according ... appears in the January 19 issue of the Journal ... randomized radiation therapy trial was designed to determine the ...
... results of a recent U.S. study, investigators in Japan ... potentially life-threatening form of high blood pressure, as reported ... Infectious Diseases, now available online. , The researchers reported ... 8 (HHV-8), also known as the Kaposi's sarcoma virus, ...
Cached Biology News:Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer 2Association of herpesvirus with lung disorder questioned 2
... StdSens analysis kit for 25 chips provides ... standard-sensitivity RNA analysis (at nanogram levels) with ... includes 25 RNA StdSens microfluidic chips, 2 ... 20 microliters RNA StdSens stain, 2 x ...
... White solid. PROTECT FROM LIGHT. PACKAGED ... soluble pyrimidinone compound that acts as a ... PARP (IC 50 = 200 nM ... respectively) with little activity against the dehydrogenase ...
... on the ease of use and flexibility of the ... introduces the BDTM LSR II. The BD LSR ... in a benchtop analyzer. Free up your high-performance ... UV laser to the BD LSR II. The BD ...
... Engine Opticon 2 real-time PCR detection system ... fluorescence excitation (470-505 nm) and two photomultiplier ... nm). The Opticon 2 system is built ... includes a thermal gradient feature. This item ...
Biology Products: